Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Leon Hooftman"'
Autor:
Ferry ALM Eskens, Jaap Verweij, Johann Sebastian De Bono, Leon Hooftman, Martin Toal, Michelle Dawn Garrett, Florence Raynaud, Adam Stewart, Matthew Tall, Phillip Debnam, Rebecca Kristeleit, Dionysis Papadatos-Pastos, Leni van Doorn, Udai Banerji
PDF file - 42K, CHR-3996
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f2832c4ab895bcac07ce8525bec35d6
https://doi.org/10.1158/1078-0432.22445493.v1
https://doi.org/10.1158/1078-0432.22445493.v1
Autor:
Ferry ALM Eskens, Jaap Verweij, Johann Sebastian De Bono, Leon Hooftman, Martin Toal, Michelle Dawn Garrett, Florence Raynaud, Adam Stewart, Matthew Tall, Phillip Debnam, Rebecca Kristeleit, Dionysis Papadatos-Pastos, Leni van Doorn, Udai Banerji
Purpose: This clinical trial investigated the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile of CHR-3996, a selective class I histone deacetylase inhibitor.Patients and Methods: CHR-3996 was administered orally once a da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d25cace9aa063042e28281fb35ae6f8
https://doi.org/10.1158/1078-0432.c.6520500
https://doi.org/10.1158/1078-0432.c.6520500
Autor:
Ferry ALM Eskens, Jaap Verweij, Johann Sebastian De Bono, Leon Hooftman, Martin Toal, Michelle Dawn Garrett, Florence Raynaud, Adam Stewart, Matthew Tall, Phillip Debnam, Rebecca Kristeleit, Dionysis Papadatos-Pastos, Leni van Doorn, Udai Banerji
PDF file - 82K, Inclusion Criteria and Analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd0b99f34bf658cee9bec738d5d8875d
https://doi.org/10.1158/1078-0432.22445490.v1
https://doi.org/10.1158/1078-0432.22445490.v1
Autor:
Faith E. Davies, Gareth J. Morgan, Leon Hooftman, Alan H. Drummond, David Krige, Brian A. Walker, Alan S. Dunlop, Srikanth Muralikrishnan, Emma M. Smith, Emma L. Davenport, Hannah E. Moore
Myeloma cells are highly dependent on the unfolded protein response to assemble folded immunoglobulins correctly. Therefore, targeting protein handling within a myeloma cell by inhibiting the aminopeptidase enzyme system, which catalyses the hydrolys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac1a66c236bf11a16b5b187d19a3964
https://doi.org/10.1158/1535-7163.c.6531419.v1
https://doi.org/10.1158/1535-7163.c.6531419.v1
Autor:
Faith E. Davies, Gareth J. Morgan, Leon Hooftman, Alan H. Drummond, David Krige, Brian A. Walker, Alan S. Dunlop, Srikanth Muralikrishnan, Emma M. Smith, Emma L. Davenport, Hannah E. Moore
Supplementary Table from Aminopeptidase inhibition as a targeted treatment strategy in myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02f6e9e3991c493a06b86dec7e567b1c
https://doi.org/10.1158/1535-7163.22484465
https://doi.org/10.1158/1535-7163.22484465
Autor:
Petronella B. Ottevanger, Willem Jan Krebber, Sanne Boekestijn, Judith R. Kroep, Gemma G. Kenter, Nikki M. Loof, Roy I. Lalisang, Hannelore Denys, Sjoerd H. van der Burg, Richard B. Stead, Cornelis J. M. Melief, Thierry Velu, Winald R. Gerritsen, Marij J. P. Welters, Anna K.L. Reyners, Brent A. Blumenstein, Frédéric Goffin, Hans W. Nijman, Sonja Visscher, Leon Hooftman, Ignace Vergote, Mariette I.E. van Poelgeest, Wiebren A.A. Tjalma
Publikováno v:
Science Translational Medicine, 12(535). AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 12(535):8235. American Association for the Advancement of Science
Science Translational Medicine, 12
Science Translational Medicine, 12(535):8235. AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 12, 535
Science translational medicine
Science Translational Medicine, 12(535):8235. American Association for the Advancement of Science
Science Translational Medicine, 12
Science Translational Medicine, 12(535):8235. AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 12, 535
Science translational medicine
Therapeutic cancer vaccines have effectively induced durable regressions of premalignant oncogenic human papilloma virus type 16 (HPV16)-induced anogenital lesions. However, the treatment of HPV16-induced cancers requires appropriate countermeasures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f17da45bfb49d86e4f147ca74e5d6333
https://doi.org/10.1126/scitranslmed.aaz8235
https://doi.org/10.1126/scitranslmed.aaz8235
Autor:
Frédéric Goffin, Mariëtte I.E. van Poelgeest, Brent A. Blumenstein, Thierry Velu, Cornelis J. M. Melief, Judith R. Kroep, Ignace Vergote, Hans W. Nijman, Marij J. P. Welters, Sjoerd H. van der Burg, Nelleke Ottevanger, Richard B. Stead, Leon Hooftman, Willem-Jan Krebber, Winald R. Gerritsen, Roy Lalisang, G.G. Kenter, Hannelore Denys, Wiebren A.A. Tjalma, Sonja Visscher, Anna K.L. Reyners
Publikováno v:
Cancer Research. 79:CT002-CT002
The therapeutic synthetic long peptide (SLP) vaccine ISA101 selectively enlarges the pool of tumor-specific T cells recognizing the human papillomavirus type 16 (HPV16) antigens E6 and E7. Vaccine monotherapy for HPV16-induced pre-malignant anogenita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::707ca04ec470f9083f7bddf1dd28d310
https://doi.org/10.1158/1538-7445.am2019-ct002
https://doi.org/10.1158/1538-7445.am2019-ct002
Autor:
Faith E. Davies, Leon Hooftman, Brian A Walker, Lauren I. Aronson, David Krige, Lei Zhang, Emma L. Davenport, Gareth J. Morgan, Alan Hastings Drummond, Emma M. Smith
Publikováno v:
Oncotarget
// Emma M. Smith 1 , Lei Zhang 1 , Brian A. Walker 1 , Emma L. Davenport 1 , Lauren I. Aronson 1 , David Krige 2 , Leon Hooftman 2 , Alan H. Drummond 2 , Gareth J. Morgan 1 and Faith E. Davies 1 1 Haemato-Oncology Research Unit, Division of Molecular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::972a6a0a493a35d3210c9e04aee5dcc8
http://europepmc.org/articles/PMC4627310
http://europepmc.org/articles/PMC4627310
Autor:
Graham M. A. Wells, Gert J. Ossenkoppele, Lindsay Bawden, Dimitri Breems, Norbert Vey, Phillip Debnam, Lindsey Ann Needham, Arjan A. van de Loosdrecht, Pierre Zachee, Martin Toal, Leon Hooftman, Alan H. Davidson, Bob Löwenberg
Publikováno v:
Ossenkoppele, G J, Lowenberg, B, Zachee, P, Vey, N, Breems, D, van de Loosdrecht, A A, Davidson, A H, Wells, G, Needham, L, Bawden, L, Toal, M, Hooftman, L & Debnam, P M 2013, ' A phase I first-in-human study with tefinostat-a monocyte/macrophage targeted histone deacetylase inhibitor-in patients with advanced haematological malignancies ', British Journal of Haematology, vol. 162, no. 2, pp. 191-201 . https://doi.org/10.1111/bjh.12359
British Journal of Haematology, 162(2), 191-201. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 162(2), 191-201. Wiley-Blackwell
British Journal of Haematology, 162(2), 191-201. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 162(2), 191-201. Wiley-Blackwell
Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi). This first-in-human, standard 3 + 3 dose escalating trial of oral, once daily tefinostat was conducted to determine the safety, tolerability, pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3736adef221487bc7ed95123677702ce
https://doi.org/10.1111/bjh.12359
https://doi.org/10.1111/bjh.12359
Autor:
Johann S. de Bono, Leon Hooftman, Alison H.M. Reid, Andrew Protheroe, Joanne Carter, Heather Shaw, Elizabeth Bone, Adrian L. Harris, Laura Vidal, Gerhardt Attard, James Spicer, Nikki Hayward
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary therapeutic activity profile of CHR-2797 (tosedostat), a novel, orally bioavailable inhibitor of the M1 family of aminopeptidases with antipro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ce1e6483cc7164afc5ebc61cb7f7735
https://doi.org/10.1158/1078-0432.ccr-09-0306
https://doi.org/10.1158/1078-0432.ccr-09-0306